Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.44 |
| ▸ | LIPC | P11150 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15640987 | 0.87 | GRIN2B (0.56) | LIPGEPHX2GRIN1GRIN2B | |
| SCHEMBL28382894 | 0.87 | GRIN2B (0.56) | LIPGEPHX2GRIN1GRIN2B | |
| SCHEMBL16242439 | 0.87 | GRIN2B (0.56) | LIPGEPHX2GRIN1GRIN2B | |
| SCHEMBL15640988 | 0.87 | GRIN2B (0.56) | LIPGEPHX2GRIN1GRIN2B | |
| SCHEMBL9597256 | 0.85 | GRIN1 (0.47) | LIPGEPHX2GRIN1GRIN2BADRB2 | |
| SCHEMBL9596793 | 0.85 | LIPG (0.46) | LIPGEPHX2GRIN1GRIN2BADRB2 | |
| SCHEMBL15640992 | 0.84 | GRIN1 (0.53) | LIPGGRIN1GRIN2BFAAH | |
| SCHEMBL15640991 | 0.84 | GRIN1 (0.53) | LIPGGRIN1GRIN2BFAAH | |
| SCHEMBL27900122 | 0.83 | ADRB2 (0.53) | LIPGEPHX2LIPCADRB2FAAH | |
| SCHEMBL20168877 | 0.83 | RIPK1 (0.47) | LIPGEPHX2GRIN1GRIN2BRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2832728-B1 | TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | NISSAN CHEMICAL IND LTD (JP) | 2018-09-05 | — | — | EP | disclosed |
| US-9403798-B2 | Triazinone compound and T-type calcium channel inhibitor | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-08-02 | — | — | US | disclosed |
| US-20150065705-A1 | TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | NISSAN CHEMICAL CORPORATION (JP) | 2015-03-05 | — | — | US | disclosed |
| EP-2832728-A1 | TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | Nissan Chemical Industries, Ltd. (JP) | 2015-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065705-A1 | TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | CACNA1E, CACNA1I, CACNA1G | LIPG 4850/4885EPHX2 4038/4885GRIN1 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.